Anti-CD2 monoclonal antibody OX34

Drug Profile

Anti-CD2 monoclonal antibody OX34

Alternative Names: CD2 antibody OX34; CD2 monoclonal antibody OX34; OX34; OX34 antibody

Latest Information Update: 23 Aug 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DKFZ; National Cancer Institute (USA)
  • Developer National Cancer Institute (USA)
  • Class Monoclonal antibodies
  • Mechanism of Action CD2 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Transplant rejection

Most Recent Events

  • 10 Aug 1998 A study has been added to the Transplant rejection pharmacodynamics section
  • 23 Dec 1996 A study has been added to the Transplant Rejection pharmacodynamics section
  • 02 Nov 1994 Preclinical development for Transplant rejection in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top